A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abelacimab (Primary) ; Abelacimab (Primary) ; Dalteparin sodium
Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
Focus Registrational; Therapeutic Use
Acronyms MAGNOLIA
Sponsors Anthos Therapeutics

Most Recent Events

11 Feb 2025 According to an Anthos Therapeutics media release,data from this trials are expected in the second half of 2026.
31 Oct 2024 Planned End Date changed from 1 Sep 2025 to 1 Feb 2027.
31 Oct 2024 Planned primary completion date changed from 1 Jun 2025 to 1 Dec 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight